Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that focuses on Innovative Medicine and MedTech. According to its public communications, the company aims to prevent, treat and cure complex diseases, make treatments less invasive, and deliver more personal healthcare solutions. Johnson & Johnson’s common stock and multiple series of notes are listed on the New York Stock Exchange, and the company is incorporated in New Jersey.

Johnson & Johnson operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. The company describes itself as a healthcare innovation powerhouse with expertise across the full spectrum of healthcare solutions. Following the divestment of its consumer business, Kenvue, its activities are organized around innovative medicines and medical technologies. Its innovative medicine division is focused on areas such as immunology, oncology, neurology and other autoantibody-driven and neuropsychiatric diseases, while its MedTech segment spans surgery, cardiovascular, orthopaedics, vision and neurovascular care.

Innovative Medicine and Therapeutic Focus

Johnson & Johnson’s innovative medicine portfolio includes therapies and investigational candidates in oncology, hematology, immunology, neuroscience and autoantibody diseases. In multiple myeloma, the company reports that it is a worldwide leader in therapies for this blood cancer. TECVAYLI (teclistamab-cqyv), described as a first-in-class bispecific T-cell engager antibody therapy targeting BCMA and CD3, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Phase 3 studies such as MajesTEC-3 and MajesTEC-9 are evaluating TECVAYLI-based regimens earlier in the treatment journey.

Johnson & Johnson also highlights a broad oncology pipeline. RYBREVANT (amivantamab-vmjw), a fully human bispecific antibody targeting EGFR and MET, is approved in the U.S., Europe and other markets for several indications in locally advanced or metastatic non-small cell lung cancer (NSCLC), both as monotherapy and in combination with chemotherapy or with LAZCLUZE (lazertinib). The company is extending the evaluation of amivantamab into colorectal cancer and other solid tumors through clinical programs such as the OrigAMI series of studies, reflecting a strategy of applying EGFR- and MET-targeted approaches across multiple tumor types.

In neuropsychiatry, Johnson & Johnson reports a portfolio and pipeline that address major depressive disorder (MDD), treatment-resistant depression (TRD), schizophrenia and bipolar disorder. CAPLYTA (lumateperone) is described as an oral, once-daily atypical antipsychotic approved in adults as an adjunctive therapy with antidepressants for MDD, for schizophrenia, and for depressive episodes associated with bipolar I or II disorder, as monotherapy or adjunctive to lithium or valproate. SPRAVATO (esketamine) CIII nasal spray is approved by the FDA, alone or with an oral antidepressant, for adults with TRD and for adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. The company also reports development of seltorexant, an investigational selective orexin-2 receptor antagonist being studied as an adjunctive treatment for adults with MDD with insomnia symptoms.

Beyond oncology and neuroscience, Johnson & Johnson is advancing therapies in autoantibody-mediated diseases. Nipocalimab, an investigational monoclonal antibody designed to bind the neonatal Fc receptor (FcRn) and reduce circulating IgG antibodies, is being evaluated across rare autoantibody diseases, maternal-fetal alloantibody conditions and rheumatic diseases. The Phase 2b JASMINE study in systemic lupus erythematosus (SLE) met its primary endpoint and key secondary and exploratory endpoints, and the company has announced plans to initiate a Phase 3 program in SLE. Regulatory agencies have granted multiple designations to nipocalimab, including orphan drug, fast track, breakthrough therapy and priority review in various indications, underscoring its potential role across a broad set of autoantibody-driven conditions.

MedTech, Surgery and Neurovascular Care

Johnson & Johnson’s MedTech businesses cover surgery, cardiovascular, orthopaedics, vision and neurovascular solutions. The company describes more than a century of involvement in surgical care, including wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Within surgery, Johnson & Johnson has developed the OTTAVA robotic surgical system, a multi-specialty soft-tissue surgery robot intended to support a broad range of procedures across patient anatomy and surgical specialties. The company has submitted OTTAVA to the FDA for De Novo classification, supported by data from an Investigational Device Exemption (IDE) study in Roux-en-Y gastric bypass procedures, and has received IDE approval for a second U.S. clinical trial in inguinal hernia procedures.

In neurovascular care, Johnson & Johnson MedTech reports that it is a leader in addressing conditions such as stroke and other cerebrovascular diseases. The TRUFILL n‑BCA Liquid Embolic System has been used in neurovascular embolization for over two decades. The FDA has approved an expanded indication for TRUFILL n‑BCA for embolization of the middle meningeal artery for the treatment of symptomatic subacute and chronic subdural hematoma as an adjunct to surgery. This indication is supported by the MEMBRANE randomized controlled trial, which demonstrated that TRUFILL n‑BCA was superior in effectiveness to standard of care for this use and was safe in the studied population. The company positions this approval as an example of its efforts to address unmet needs in chronic subdural hematoma, particularly for patients at risk of recurrence or complications from surgery.

Across cardiovascular solutions, Johnson & Johnson MedTech notes that it provides technologies for advanced mapping and navigation, miniaturized devices and precise ablation to address heart failure, coronary artery disease, stroke and atrial fibrillation. The company describes itself as a global leader in heart recovery, circulatory restoration and treatment of heart rhythm disorders, and as an emerging leader in neurovascular care, focusing on two of the leading causes of death worldwide: heart failure and stroke.

Research, Development and Strategic Transactions

Johnson & Johnson emphasizes its investment in research and development to advance new therapeutic platforms and technologies. The acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company, adds a proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform to its oncology portfolio. Through this transaction, Johnson & Johnson gains HLD-0915, a once-daily oral therapy candidate for prostate cancer designed to overcome resistance mechanisms via targeted tumor cell eradication, as well as earlier-stage candidates for breast, lung and other tumor types. The company indicates that the RIPTAC platform may also support development of targeted therapies beyond oncology.

In neuroscience discovery, Johnson & Johnson has presented research on AI-enabled platforms and novel mechanisms at scientific meetings. For example, it has described the NAIO (Neuroscience and AI-Optimized) platform, a multi-modal computational platform intended to inform target and indication selection, biomarker readouts and patient stratification in central nervous system drug development. The company also reports preclinical work on new therapeutic mechanisms for depression and investigations into neuropsychiatric disease biology, reflecting a broad approach that spans basic science, translational research and clinical development.

Johnson & Johnson’s SEC filings illustrate its scale and access to capital markets. The company’s common stock trades on the New York Stock Exchange under the symbol JNJ, and multiple series of notes with maturities extending into the 2050s are also listed. Periodic Form 8-K filings report quarterly sales and earnings and other material events, such as the company’s stated intent to separate its Orthopaedics business, indicating ongoing portfolio evolution within MedTech.

Manufacturing Footprint and U.S. Investment

Johnson & Johnson has announced significant manufacturing and innovation investments in the United States. The company references a multi-year, multibillion-dollar U.S. investment program intended to support manufacturing, research and development, and technology. As part of this effort, it is developing new manufacturing facilities, including a next-generation cell therapy manufacturing site in Pennsylvania and a drug product manufacturing facility in North Carolina. It has also described construction of a large biologics manufacturing facility in Wilson, North Carolina, and a dedicated biopharmaceutical manufacturing site in Holly Springs, North Carolina, as part of its plan to manufacture the vast majority of its advanced medicines in the U.S. to meet domestic patient needs.

Johnson & Johnson has also entered into a voluntary agreement with the U.S. government to improve access to medicines and lower costs for American patients. Under this agreement, the company plans to participate in a direct-to-patient platform that offers its medicines at discounted rates, enable access at prices comparable to other developed countries, and provide Medicaid program access at similar price levels. The agreement also provides exemptions from certain U.S. tariffs for its pharmaceutical products, aligning with the company’s stated goal of supporting both patient access and U.S. healthcare innovation.

Dividends, Capital Returns and Corporate Structure

Johnson & Johnson’s Board of Directors periodically declares cash dividends on the company’s common stock. For example, the company announced a cash dividend for the first quarter of 2026, payable to shareholders of record on a specified date. Such announcements, disclosed via Form 8-K and press releases, reflect the company’s practice of returning capital to shareholders while continuing to invest in innovation, manufacturing and strategic acquisitions.

In its SEC filings, Johnson & Johnson identifies itself as a New Jersey corporation with a Commission File Number of 1-3215 and a federal employer identification number. Its securities registered under Section 12(b) of the Securities Exchange Act include common stock and various series of notes, each with its own trading symbol on the New York Stock Exchange. These disclosures provide transparency into the company’s capital structure and reporting obligations as a large, publicly traded issuer.

Position in the Healthcare Ecosystem

Through its combination of innovative medicines, medical technologies, manufacturing investments and clinical research, Johnson & Johnson positions itself as a company that addresses complex and pervasive health challenges. It reports activity across cancer, cardiovascular disease, mental health, autoimmune and autoantibody-mediated conditions, neurovascular disease and surgical care. By integrating pharmaceutical preparation manufacturing with MedTech capabilities, the company seeks to deliver therapies, devices and digital tools that can be used across the continuum of care, from prevention and diagnosis to treatment and long-term management.

According to its public statements, Johnson & Johnson’s overarching goal is to "profoundly impact health for humanity" by building a world where complex diseases are prevented, treated and cured, where treatments are smarter and less invasive, and where solutions are tailored to individual patient needs. Its ongoing clinical programs, regulatory submissions, manufacturing expansions and strategic acquisitions all contribute to this long-term vision as described in its press releases and regulatory filings.